tradingkey.logo


tradingkey.logo


Amarin Corporation PLC

AMRN
13.949USD
+0.349+2.56%
取匕時間 ET15分遅れの株䟡
290.11M時䟡総額
損倱額盎近12ヶ月PER


Amarin Corporation PLC

13.949
+0.349+2.56%

詳现情報 Amarin Corporation PLC 䌁業名

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Amarin Corporation PLCの䌁業情報


䌁業コヌドAMRN
䌚瀟名Amarin Corporation PLC
䞊堎日Apr 01, 1993
最高経営責任者「CEO」Berg (Aaron D)
埓業員数275
蚌刞皮類Depository Receipt
決算期末Apr 01
本瀟所圚地WeWork One Central Plaza Dame Street
郜垂DUBLIN
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜Ireland
郵䟿番号D02 K7K5
電話番号35316699020
りェブサむトhttps://amarincorp.com/
䌁業コヌドAMRN
䞊堎日Apr 01, 1993
最高経営責任者「CEO」Berg (Aaron D)

Amarin Corporation PLCの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. David Keenan, Ph.D.
Dr. David Keenan, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
7.95K
--
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Mr. Oliver O'Connor
Mr. Oliver O'Connor
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Dr. Paul Cohen, M.D.
Dr. Paul Cohen, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Ms. Patrice Bonfiglio
Ms. Patrice Bonfiglio
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Louis Sterling, III
Mr. Louis Sterling, III
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Peter Fishman
Mr. Peter Fishman
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Stephen B. (Steven) Ketchum, Ph.D.
Dr. Stephen B. (Steven) Ketchum, Ph.D.
President - Research and Development, Executive Vice President, Chief Scientific Officer
President - Research and Development, Executive Vice President, Chief Scientific Officer
--
--
Mr. Aaron D. Berg
Mr. Aaron D. Berg
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Keith L. Horn
Mr. Keith L. Horn
Non-Executive Independent Director
Non-Executive Independent Director
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. David Keenan, Ph.D.
Dr. David Keenan, Ph.D.
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
7.95K
--
Ms. Diane E. Sullivan
Ms. Diane E. Sullivan
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Mr. Oliver O'Connor
Mr. Oliver O'Connor
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Dr. Paul Cohen, M.D.
Dr. Paul Cohen, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
401.00
--
Ms. Patrice Bonfiglio
Ms. Patrice Bonfiglio
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Louis Sterling, III
Mr. Louis Sterling, III
Non-Executive Independent Director
Non-Executive Independent Director
--
--

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Sun, Nov 16
曎新時刻: Sun, Nov 16
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Sarissa Capital Management, L.P.
5.98%
Kynam Capital Management LP
2.77%
Acadian Asset Management LLC
2.20%
Morgan Stanley & Co. LLC
1.21%
Eversept Partners, LP
0.80%
他の
87.04%
株䞻統蚈
株䞻統蚈
比率
Sarissa Capital Management, L.P.
5.98%
Kynam Capital Management LP
2.77%
Acadian Asset Management LLC
2.20%
Morgan Stanley & Co. LLC
1.21%
Eversept Partners, LP
0.80%
他の
87.04%
皮類
株䞻統蚈
比率
Hedge Fund
12.07%
Investment Advisor/Hedge Fund
2.95%
Investment Advisor
2.79%
Research Firm
1.93%
Individual Investor
0.99%
Pension Fund
0.35%
Family Office
0.24%
他の
78.69%

機関投資家保有株


曎新時刻: Mon, Dec 8
曎新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q4
291
4.18M
22.49%
+4.06K
2025Q3
314
4.20M
24.13%
+467.66K
2025Q2
330
3.80M
23.58%
+94.36K
2025Q1
338
3.76M
23.88%
-1.19M
2024Q4
355
3.75M
23.57%
+236.09K
2024Q3
360
3.51M
29.65%
-554.68K
2024Q2
386
4.06M
34.43%
-548.92K
2024Q1
399
4.62M
36.64%
-2.90M
2023Q4
416
4.89M
38.80%
+197.93K
2023Q3
435
4.67M
42.33%
-650.41K
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Sarissa Capital Management, L.P.
1.24M
6.01%
-4.00
-0.00%
Jun 30, 2025
Kynam Capital Management LP
576.11K
2.79%
-44.62K
-7.19%
Jun 30, 2025
Acadian Asset Management LLC
241.05K
1.17%
+51.47K
+27.15%
Jun 30, 2025
Morgan Stanley & Co. LLC
147.27K
0.71%
+31.23K
+26.91%
Jun 30, 2025
Eversept Partners, LP
167.28K
0.81%
-2.68K
-1.58%
Jun 30, 2025
Millennium Management LLC
45.24K
0.22%
+44.25K
+4470.10%
Jun 30, 2025
Citadel Advisors LLC
45.46K
0.22%
+45.46K
--
Jun 30, 2025
SCP Investment, LP
125.00K
0.6%
--
--
Jun 30, 2025
BNP Paribas Securities Corp. North America
75.94K
0.37%
+4.35K
+6.07%
Jun 30, 2025
Longitude (Cayman) Ltd
81.00K
0.39%
-37.50K
-31.65%
Dec 31, 2024
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.03%
SPDR S&P International Small Cap ETF
0.02%
Global X Aging Population ETF
0%
ActivePassive International Equity ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
ProShares Ultra Nasdaq Biotechnology
比率0.04%
Invesco Nasdaq Biotechnology ETF
比率0.03%
SPDR S&P International Small Cap ETF
比率0.02%
Global X Aging Population ETF
比率0%
ActivePassive International Equity ETF
比率0%
Invesco NASDAQ Future Gen 200 ETF
比率0%
SPDR Portfolio Developed World ex-US ETF
比率0%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
皮類
比率
Mar 12, 2025
Merger
20→1
Mar 12, 2025
Merger
20→1
日付
皮類
比率
Mar 12, 2025
Merger
20→1
Mar 12, 2025
Merger
20→1

よくある質問

Amarin Corporation PLCの䞊䜍5名の株䞻は誰ですか


Amarin Corporation PLCの䞊䜍5名の株䞻は以䞋のずおりです。
Sarissa Capital Management, L.P.は1.24M株を保有しおおり、これは党䜓の6.01%に盞圓したす。
Kynam Capital Management LPは576.11K株を保有しおおり、これは党䜓の2.79%に盞圓したす。
Acadian Asset Management LLCは241.05K株を保有しおおり、これは党䜓の1.17%に盞圓したす。
Morgan Stanley & Co. LLCは147.27K株を保有しおおり、これは党䜓の0.71%に盞圓したす。
Eversept Partners, LPは167.28K株を保有しおおり、これは党䜓の0.81%に盞圓したす。

Amarin Corporation PLCの株䞻タむプ䞊䜍3皮は䜕ですか


Amarin Corporation PLCの株䞻タむプ䞊䜍3皮は、
Sarissa Capital Management, L.P.
Kynam Capital Management LP
Acadian Asset Management LLC

Amarin Corporation PLCAMRNの株匏を保有しおいる機関の数はいく぀ですか


2025Q4時点で、Amarin Corporation PLCの株匏を保有しおいる機関は291瀟あり、保有株匏の総垂堎䟡倀は玄4.18Mで、党䜓の22.49%を占めおいたす。2025Q3ず比范しお、機関の持ち株は-1.63%増加しおいたす。

Amarin Corporation PLCの最倧の収益源は䜕ですか


--においお、--郚門がAmarin Corporation PLCにずっお最倧の収益を生み出しおおり、その金額は--で、党収益の--%を占めおいたす。
KeyAI
î™